Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab + Becotatug Vedotin in locally advanced resectable HNSCC
NCT07586124Phase 2Recruiting
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Becotatug Vedotin + Pucotenlimab with Placebo + Pucotenlimab (2 arms). Primary endpoint: Major Pathological Response Rate up to 8 weeks. Started Jul 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07586124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586124.